ES2054617T3 - Nuevo metodo para la deteccion y/o determinacion cuantitativa de agentes ligantes especificos y sus correspondientes sustancias ligables. - Google Patents

Nuevo metodo para la deteccion y/o determinacion cuantitativa de agentes ligantes especificos y sus correspondientes sustancias ligables.

Info

Publication number
ES2054617T3
ES2054617T3 ES86202231T ES86202231T ES2054617T3 ES 2054617 T3 ES2054617 T3 ES 2054617T3 ES 86202231 T ES86202231 T ES 86202231T ES 86202231 T ES86202231 T ES 86202231T ES 2054617 T3 ES2054617 T3 ES 2054617T3
Authority
ES
Spain
Prior art keywords
latex particles
specific binding
colour
colourable
coloured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86202231T
Other languages
English (en)
Inventor
Jaeger Nikolaas C J De
Marcel J Monbaliu
Marcus J M Noppe
Frank J Konings
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2054617T3 publication Critical patent/ES2054617T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/80—Fluorescent dyes, e.g. rhodamine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/805—Optical property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/823—Immunogenic carrier or carrier per se
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Paper (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

UN METODO PARA DETERMINAR CUALI Y CUANTITATIVAMENTE UN COMPONENTE DE UN COMPLEJO FORMADO ENTRE AL MENOS UN AGENTE LIGANTE ESPECIFICO Y SU CORRESPONDIENTE SUSTANCIA LIGABLE. DICHO METODO CONSISTE EN MARCAR AL MENOS UN COMPONENTE DE DICHO COMPLEJO CON UN MARCADOR QUE SE DETERMINA MAS FACILMENTE QUE EL PROPIO COMPLEJO, DONDE EL MARCADOR USADO CONSTA DE PARTICULAS DE LATEX QUE SE PUEDEN DETERMINAR VISUALMENTE POR COLOR O FLUORESCENCIA. PREFERIBLEMENTE EL MARCADOR CONSTA DE PARTICULAS DE LATEX COLOREADAS O COLOREABLES, Y LA DETERMINACION SE BASA EN LAS CARACTERISTICAS DE COLOR DE LAS PARTICULAS DE LATEX COMO TALES, O EN EL CASO DE QUE SE USEN PARTICULAS COLOREABLES, EN LAS CARACTERISTICAS DE COLOR DE LAS PARTICULAS COLOREADAS PROCEDENTES DE ELLAS. EL COLOR O SEÑAL DE FLUORESCENCIA, SE DETECTA FACILMENTE, SI ES NECESARIO DESPUES DE DESARROLLAR Y, OPCIONALMENTE, CUANTIFICA. LA INVENCION, ADEMAS, COMPRENDE PARTICULAS DE LATEX COLOREADAS O COLOREABLES REVESTIDAS CON PROTEINAS CON UNION ESPECIFICA YEQUIPOS DE ENSAYO QUE LAS CONTIENEN.
ES86202231T 1985-12-23 1986-12-10 Nuevo metodo para la deteccion y/o determinacion cuantitativa de agentes ligantes especificos y sus correspondientes sustancias ligables. Expired - Lifetime ES2054617T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81258685A 1985-12-23 1985-12-23

Publications (1)

Publication Number Publication Date
ES2054617T3 true ES2054617T3 (es) 1994-08-16

Family

ID=25210046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86202231T Expired - Lifetime ES2054617T3 (es) 1985-12-23 1986-12-10 Nuevo metodo para la deteccion y/o determinacion cuantitativa de agentes ligantes especificos y sus correspondientes sustancias ligables.

Country Status (7)

Country Link
US (2) US4837168A (es)
EP (1) EP0227173B1 (es)
JP (1) JP2509201B2 (es)
AT (1) ATE87743T1 (es)
CA (1) CA1291031C (es)
DE (1) DE3688184T2 (es)
ES (1) ES2054617T3 (es)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622871A (en) 1987-04-27 1997-04-22 Unilever Patent Holdings B.V. Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents
US4997772A (en) * 1987-09-18 1991-03-05 Eastman Kodak Company Water-insoluble particle and immunoreactive reagent, analytical elements and methods of use
ES2150428T3 (es) * 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5194300A (en) * 1987-07-15 1993-03-16 Cheung Sau W Methods of making fluorescent microspheres
IT1217993B (it) * 1988-02-01 1990-03-30 Boehringer Biochemia Srl Metodo analitico impiegante reagneti biospecifici marcati con macromolecole colorate
JPH01214760A (ja) * 1988-02-23 1989-08-29 Teikoku Hormone Mfg Co Ltd 免疫学的簡易測定方法
US5145784A (en) * 1988-05-04 1992-09-08 Cambridge Biotech Corporation Double capture assay method employing a capillary flow device
US5252459A (en) * 1988-09-23 1993-10-12 Abbott Laboratories Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
FR2638848B1 (fr) * 1988-11-04 1993-01-22 Chemunex Sa Procede de detection et/ou de dosage dans un milieu liquide ou semi-liquide d'au moins une substance organique, biologique ou medicamenteuse soluble, par une methode d'agglutination
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5547839A (en) * 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
CA2016999A1 (en) * 1989-07-19 1991-01-19 Sunil G. Anaokar Assay method and apparatus
JPH05504195A (ja) * 1990-02-22 1993-07-01 ザ・ロイヤル・インステイチユーシヨン・フオー・ジ・アドバンスメント・オブ・ラーニング　（マクギル・ユニバーシテイ） 固相干渉イムノアッセイ系
CA2088195A1 (en) * 1990-08-31 1992-03-01 David C. Horwell Cholecystokinin antagonists, their preparation and therapeutic use
US5266497A (en) * 1990-08-31 1993-11-30 Japan Synthetic Rubber Co., Ltd. Immunochromatographic assay with improved colored latex
DE69126142T2 (de) * 1990-09-26 1997-09-11 Akers Lab Inc Verbessertes bestimmungsverfahren für liganden
JPH0737990B2 (ja) * 1990-10-12 1995-04-26 寳酒造株式会社 糖類の標識方法及び糖類標識用キット
US5192510A (en) * 1991-01-30 1993-03-09 E. I. Du Pont De Nemours And Company Apparatus for performing fluorescent assays which separates bulk and evanescent fluorescence
FR2673292A1 (fr) * 1991-02-26 1992-08-28 Sebia Sa Procede d'immunofixation ou d'immunoelectrophorese a l'aide d'un ensemble d'au moins deux immunserums differents ou deux solutions d'immunoglobulines differentes et kit pour la mise en óoeuvre d'un tel procede.
WO1992020746A1 (en) * 1991-05-14 1992-11-26 Hybritech, Incorporated Polymeric compositions having bound antibodies
US5877028A (en) 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5998220A (en) 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5395754A (en) * 1992-07-31 1995-03-07 Hybritech Incorporated Membrane-based immunoassay method
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
BE1006245A3 (fr) * 1993-05-03 1994-06-14 Ape Associates As Reactifs pour la detection ou le dosage d'un analyte dans un echantillon, trousses les contenant, et procede de detection ou de dosage utilisant ces reactifs.
US5352585A (en) * 1993-06-29 1994-10-04 Bio-Rad Laboratories, Inc. System for benzodiazepine detection
CH686518A5 (de) * 1993-10-05 1996-04-15 Asahi Optical Co Ltd Granulares Polymerkomposit, Herstellungsverfahren fur dieses und diagnostische Mittel.
GB2314333B (en) * 1993-10-05 1998-04-29 Asahi Optical Co Ltd Antigen or antibody immobilised on dyed composite comprising polymer granules coated with a calcium phosphate
CA2167362A1 (en) * 1995-02-10 1996-08-11 Alexei Dmitri Klimov Apparatus and method for conducting a binding assay on an absorbent carrier material
WO1997000271A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US7455964B1 (en) 1996-07-15 2008-11-25 The Hospital For Sick Children Genes from the 20q13 amplicon and their uses
US6586193B2 (en) * 1996-04-25 2003-07-01 Genicon Sciences Corporation Analyte assay using particulate labels
IL126544A (en) 1996-04-25 2004-08-31 Genicon Sciences Inc Analyte assay using scattered-light detectable particles
DE19621312A1 (de) 1996-05-28 1997-12-04 Bayer Ag Maskierung der Hintergrundfluoreszenz und Signalverstärkung bei der optischen Analyse biologisch medizinischer Assays
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US5879951A (en) 1997-01-29 1999-03-09 Smithkline Diagnostics, Inc. Opposable-element assay device employing unidirectional flow
EP2172478A3 (en) 1997-02-07 2010-07-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Activity-dependent neurotrophic factor III (ADNF III)
US5981296A (en) * 1997-02-18 1999-11-09 Dade Behring Inc. Stabilization of particle reagents
US6103536A (en) 1997-05-02 2000-08-15 Silver Lake Research Corporation Internally referenced competitive assays
US5939252A (en) 1997-05-09 1999-08-17 Lennon; Donald J. Detachable-element assay device
US6960457B1 (en) * 1997-09-04 2005-11-01 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
US7713703B1 (en) 2000-11-13 2010-05-11 Biosite, Inc. Methods for monitoring the status of assays and immunoassays
US6194222B1 (en) * 1998-01-05 2001-02-27 Biosite Diagnostics, Inc. Methods for monitoring the status of assays and immunoassays
US6265163B1 (en) 1998-01-09 2001-07-24 Lynx Therapeutics, Inc. Solid phase selection of differentially expressed genes
US6764830B1 (en) 1998-01-23 2004-07-20 The Regents Of The University Of California Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
ATE273516T1 (de) * 1999-06-23 2004-08-15 Cornell Res Foundation Inc Entwässerung/rehydratisierung von markierten liposomen auf einer prüfeinrichtung
US6703248B1 (en) * 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
DK1287364T3 (da) 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
DE10042023C2 (de) * 2000-08-08 2003-04-10 Biognostic Ag Kapseln, die feste Teilchen signalerzeugender Substanzen einkapseln, und deren Verwendung bei Bioassays zum Nachweis von Zielmolekülen in einer Probe
GB0021303D0 (en) * 2000-08-30 2000-10-18 Medinnova Sf Use
WO2002026107A2 (en) * 2000-09-25 2002-04-04 The Regents Of The University Of California Model for neurodegenerative diseases involving amyloid accumulation
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
US7691645B2 (en) * 2001-01-09 2010-04-06 Agilent Technologies, Inc. Immunosubtraction method
US7361472B2 (en) * 2001-02-23 2008-04-22 Invitrogen Corporation Methods for providing extended dynamic range in analyte assays
EP1412750B1 (en) 2001-06-26 2012-05-23 Senomyx, Inc. T1r2-t1r3 hetero-oligomeric sweet taste receptors and cell lines that express said receptors and use thereof for identification of sweet taste compounds
US7300633B2 (en) 2001-07-25 2007-11-27 Oakville Hong Kong Company Limited Specimen collection container
US7270959B2 (en) 2001-07-25 2007-09-18 Oakville Hong Kong Company Limited Specimen collection container
JP4265149B2 (ja) * 2001-07-25 2009-05-20 セイコーエプソン株式会社 電気光学装置、電気光学装置の製造方法
AU2002331897A1 (en) 2001-09-27 2003-04-07 Pioneer Hi-Bred International, Inc. Phytate polynucleotides and methods of use
US20030099621A1 (en) 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
US8367013B2 (en) 2001-12-24 2013-02-05 Kimberly-Clark Worldwide, Inc. Reading device, method, and system for conducting lateral flow assays
US6837171B1 (en) 2002-04-29 2005-01-04 Palmer/Snyder Furniture Company Lightweight table with unitized table top
US20030119203A1 (en) 2001-12-24 2003-06-26 Kimberly-Clark Worldwide, Inc. Lateral flow assay devices and methods for conducting assays
US20060088830A1 (en) * 2002-02-21 2006-04-27 Eastern Virginia Medical School Protein biomarkers that distinguish prostate cancer from non-malignant cells
US20030162178A1 (en) * 2002-02-25 2003-08-28 O'hagan David Variable microarray and methods of detecting one or more anlaytes in a sample
ATE478337T1 (de) * 2002-05-31 2010-09-15 Cornell Res Foundation Inc Methoden zum nachweis analyten in proben
ATE541047T1 (de) 2002-08-01 2012-01-15 Univ California Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
CA2745724C (en) 2002-08-23 2015-06-02 Bayer Schering Pharma Aktiengesellschaft Biomarkers comprising peptide sequence vnhvtlsqpk for diagnosing alzheimer's disease
US7314763B2 (en) * 2002-08-27 2008-01-01 Kimberly-Clark Worldwide, Inc. Fluidics-based assay devices
US7285424B2 (en) 2002-08-27 2007-10-23 Kimberly-Clark Worldwide, Inc. Membrane-based assay devices
US7432105B2 (en) 2002-08-27 2008-10-07 Kimberly-Clark Worldwide, Inc. Self-calibration system for a magnetic binding assay
ES2525318T3 (es) * 2002-10-11 2014-12-22 Zbx Corporation Dispositivos de diagnóstico
US7781172B2 (en) 2003-11-21 2010-08-24 Kimberly-Clark Worldwide, Inc. Method for extending the dynamic detection range of assay devices
US20040106190A1 (en) * 2002-12-03 2004-06-03 Kimberly-Clark Worldwide, Inc. Flow-through assay devices
US20040121334A1 (en) * 2002-12-19 2004-06-24 Kimberly-Clark Worldwide, Inc. Self-calibrated flow-through assay devices
US7247500B2 (en) 2002-12-19 2007-07-24 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in membrane-based assay devices
JP2006512075A (ja) * 2002-12-31 2006-04-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー イヌｃｙｐ１ａ２配列
JP2006512076A (ja) * 2002-12-31 2006-04-13 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー イヌ（ｃａｎｉｎｅ）Ｌ−ＰＢＥ配列
WO2004057940A2 (en) * 2002-12-31 2004-07-15 Pharmacia & Upjohn Company Llc Canine dioxin/aryl hydrocarbon receptor sequences
US7560272B2 (en) 2003-01-04 2009-07-14 Inverness Medical Switzerland Gmbh Specimen collection and assay container
US6977079B2 (en) * 2003-01-17 2005-12-20 Regents Of The University Of Minnesota Avian pneumovirus vaccine
EP1594900A2 (en) * 2003-02-14 2005-11-16 Salmedix, Inc. Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
US7851209B2 (en) * 2003-04-03 2010-12-14 Kimberly-Clark Worldwide, Inc. Reduction of the hook effect in assay devices
US20040197819A1 (en) 2003-04-03 2004-10-07 Kimberly-Clark Worldwide, Inc. Assay devices that utilize hollow particles
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
WO2004110384A2 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. Hiv-1 envelope glycoproteins having unusual disulfide structure
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
US20050019214A1 (en) * 2003-07-23 2005-01-27 Eastman Kodak Company Colorable polymeric particles with biological probes
US6914106B2 (en) * 2003-07-23 2005-07-05 Eastman Kodak Company Polymer microspheres containing latent colorants and method of preparation
EP1659881B1 (en) 2003-08-06 2019-04-03 Senomyx Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
US7517495B2 (en) 2003-08-25 2009-04-14 Inverness Medical Switzerland Gmbh Biological specimen collection and analysis system
US20050079484A1 (en) * 2003-10-10 2005-04-14 Heineman William Richard Method of detecting biological materials in liquid
EP1689887B1 (en) 2003-10-21 2012-03-21 Orion Genomics, LLC Methods for quantitative determination of methylation density in a dna locus
US20050112703A1 (en) 2003-11-21 2005-05-26 Kimberly-Clark Worldwide, Inc. Membrane-based lateral flow assay devices that utilize phosphorescent detection
US7943395B2 (en) 2003-11-21 2011-05-17 Kimberly-Clark Worldwide, Inc. Extension of the dynamic detection range of assay devices
US7713748B2 (en) 2003-11-21 2010-05-11 Kimberly-Clark Worldwide, Inc. Method of reducing the sensitivity of assay devices
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
US7943089B2 (en) 2003-12-19 2011-05-17 Kimberly-Clark Worldwide, Inc. Laminated assay devices
US20050141843A1 (en) * 2003-12-31 2005-06-30 Invitrogen Corporation Waveguide comprising scattered light detectable particles
EP1713900A4 (en) * 2004-01-27 2009-06-17 Compugen Ltd METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES
WO2005089316A2 (en) 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
EP2520310B1 (en) 2004-04-23 2016-03-30 Zoetis Services LLC Cellular permissivity factor for viruses, and uses thereof
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
CA2571452A1 (en) * 2004-06-18 2006-01-26 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US20080268426A1 (en) * 2004-06-18 2008-10-30 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
US7521226B2 (en) 2004-06-30 2009-04-21 Kimberly-Clark Worldwide, Inc. One-step enzymatic and amine detection technique
EP1784510A4 (en) * 2004-08-02 2010-08-04 Janssen Pharmaceutica Nv IRAK1C SPLICE VARIANT AND USE THEREOF
WO2006023312A2 (en) 2004-08-20 2006-03-02 Carl Deirmengian Diagnostic assay for source of inflammation
US7893197B2 (en) * 2004-08-25 2011-02-22 Janssen Pharmaceutica N.V. Relaxin-3 chimeric polypeptides and their preparation and use
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2007094754A2 (en) 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
ES2732071T3 (es) * 2005-04-01 2019-11-20 Univ Florida Biomarcadores de lesiones hepáticas
US8048638B2 (en) * 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
US8124350B2 (en) 2005-04-04 2012-02-28 Biogen Idec Ma Inc. Methods and products for evaluating an immune response to a therapeutic protein
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
PL1904631T3 (pl) 2005-06-24 2012-10-31 Univ Minnesota Wirusy PRRS, klony zakaźne, ich mutanty i sposoby stosowania
US7642086B2 (en) 2005-08-09 2010-01-05 Canon Kabushiki Kaisha Labeled probe bound object, method for producing the same and method for using the same
EP1939637A4 (en) 2005-09-01 2011-02-23 Murata Manufacturing Co METHOD AND DEVICE FOR MEASURING THE STREUKOEFFICIENT OF A SUBJECT
US8193328B2 (en) * 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
WO2007053524A2 (en) * 2005-10-28 2007-05-10 The Florida International University Board Of Trustees Horse: human chimeric antibodies
US20100028358A1 (en) 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
EP2564864B8 (en) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University FGF2-related methods for diagnosing and treating depression
US7763453B2 (en) 2005-11-30 2010-07-27 Micronics, Inc. Microfluidic mixing and analytic apparatus
US9056291B2 (en) 2005-11-30 2015-06-16 Micronics, Inc. Microfluidic reactor system
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP3147665A1 (en) 2005-12-22 2017-03-29 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP1973945A4 (en) 2006-01-16 2009-11-18 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS
HUE047230T2 (hu) 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
AU2007265628B2 (en) * 2006-06-23 2012-12-06 Revvity Health Sciences, Inc. Methods and devices for microfluidic point-of-care immunoassays
WO2008021954A2 (en) * 2006-08-09 2008-02-21 Biogen Idec Ma Inc. Method for distribution of a drug
US7569396B1 (en) 2006-09-08 2009-08-04 Purplecow Llc Caffeine detection using internally referenced competitive assays
US7919331B2 (en) * 2006-12-21 2011-04-05 Silver Lake Research Corporation Chromatographic test strips for one or more analytes
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US7572990B2 (en) * 2007-03-30 2009-08-11 Intermec Ip Corp. Keypad overlay membrane
EP2155238B1 (en) 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
WO2009025364A1 (ja) 2007-08-23 2009-02-26 Mitsubishi Kagaku Iatron, Inc. 非特異反応抑制剤
SI2769729T1 (sl) 2007-09-04 2019-06-28 Compugen Ltd. Polipeptidin in polinukleotidi in njihove uporabe kot tarča zdravila za izdelavo zdravil in bioloških zdravil
AU2009208607B2 (en) * 2008-01-31 2013-08-01 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2009258038A1 (en) 2008-03-14 2009-12-17 Eastern Virginia Medical School Imaging mass spectrometry for improved prostate cancer diagnostics
US8993231B2 (en) * 2008-03-18 2015-03-31 Marshall University Research Corporation Methods for stem cell production and therapy
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20100021472A1 (en) * 2008-07-25 2010-01-28 Geetha Srikrishna Methods for diagnosing and treating cancer
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
EP3336551B1 (en) 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
AU2008360729A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
WO2010061393A1 (en) 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
CA2743707A1 (en) 2008-12-04 2010-06-10 Pioneer Hi-Bred International, Inc. Methods and compositions for enhanced yield by targeted expression of knotted1
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2010241947B2 (en) 2009-03-27 2014-01-16 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
GB2470939A (en) 2009-06-10 2010-12-15 Dna Supernova Ltd Signal amplification microspheres
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
EP2485762B1 (en) 2009-10-11 2017-12-13 Biogen MA Inc. Anti-vla-4 related assays
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
BR112012017014B1 (pt) 2010-01-11 2021-07-20 Biogen Ma Inc Métodos para detecção de anticorpos de vírus jc
JP6063378B2 (ja) 2010-01-26 2017-01-18 バンヤン・バイオマーカーズ・インコーポレイテッド アルギニノコハク酸合成酵素に関係する組成物および方法
WO2011094577A2 (en) 2010-01-29 2011-08-04 Micronics, Inc. Sample-to-answer microfluidic cartridge
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2011106738A2 (en) 2010-02-25 2011-09-01 Fred Hutchinson Cancer Research Center Use of tcr clonotypes as biomarkers for disease
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
US8383580B2 (en) 2010-06-10 2013-02-26 The Regents Of The University Of Michigan Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
EP2616100B1 (en) 2010-09-17 2016-08-31 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2622091B1 (en) 2010-09-23 2019-03-13 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
EP2477032A1 (en) 2011-01-18 2012-07-18 Baxter International Inc Measurement of anti-amyloid antibodies in human blood
JP2014507649A (ja) 2011-01-18 2014-03-27 バクスター・インターナショナル・インコーポレイテッド ヒト血液中の抗βアミロイド抗体の測定
CA2832565A1 (en) 2011-04-08 2012-10-11 Biogen Idec Ma Inc. Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
US9067997B2 (en) 2011-05-25 2015-06-30 Innate Pharma Sa Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
HUE061244T2 (hu) 2011-05-31 2023-06-28 Biogen Ma Inc A PML kockázat értékelésének módszere
JP2014527036A (ja) 2011-06-27 2014-10-09 ザ ジャクソン ラボラトリー 癌および自己免疫疾患の処置のための方法および組成物
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
US9835621B2 (en) 2011-07-14 2017-12-05 University Of Kentucky Research Foundation Process for detection of alzheimer's disease from a serum sample
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
EP2758775B1 (en) 2011-09-22 2017-08-16 Medicinal Bioconvergence Research Center Novel use of leucyl trna synthetase
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CN104136123B (zh) 2012-01-09 2017-03-01 精密公司 微流体反应器系统
EP2807271B1 (en) 2012-01-24 2018-08-22 CD Diagnostics, Inc. System for detecting infection in synovial fluid
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
KR101353930B1 (ko) 2012-02-20 2014-01-27 주식회사 나노엔텍 신규한 항원의 검출방법 및 그를 이용한 장치
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
HK1213044A1 (zh) 2012-08-03 2016-06-24 Foundation Medicine, Inc. 人乳头瘤病毒作为肿瘤预後的预测因子
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
EP2895623B1 (en) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
WO2014063205A1 (en) 2012-10-26 2014-05-01 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
CN104884637A (zh) 2012-11-05 2015-09-02 普隆奈治疗公司 利用生物标志物通过bcl2表达的调节治疗癌症的方法
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
JP2016509206A (ja) 2012-12-21 2016-03-24 マイクロニクス， インコーポレイテッド 携帯型蛍光検出システムおよびマイクロアッセイカートリッジ
WO2014100732A1 (en) 2012-12-21 2014-06-26 Micronics, Inc. Fluidic circuits and related manufacturing methods
US10518262B2 (en) 2012-12-21 2019-12-31 Perkinelmer Health Sciences, Inc. Low elasticity films for microfluidic use
EP3336104A1 (en) 2012-12-28 2018-06-20 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20160039917A1 (en) 2013-03-15 2016-02-11 Velo Bio, Llc Method for Treating Eclampsia and Preeclampsia
CN105228641A (zh) 2013-03-21 2016-01-06 密歇根大学董事会 治疗代谢紊乱的方法
WO2014182661A2 (en) 2013-05-06 2014-11-13 Alnylam Pharmaceuticals, Inc Dosages and methods for delivering lipid formulated nucleic acid molecules
CA2911303C (en) 2013-05-07 2021-02-16 Micronics, Inc. Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions
WO2014182844A1 (en) 2013-05-07 2014-11-13 Micronics, Inc. Microfluidic devices and methods for performing serum separation and blood cross-matching
CN105189784B (zh) 2013-05-07 2020-06-30 珀金埃尔默健康科学有限公司 用于制备和分析核酸的装置
EP3004334A4 (en) 2013-05-28 2016-12-21 Biogen Ma Inc METHOD FOR ASSESSING A PML RISK
HK1224331A1 (zh) 2013-07-17 2017-08-18 Foundation Medicine, Inc. 治疗尿路上皮癌的方法
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2015063604A2 (en) 2013-11-01 2015-05-07 Imberti Luisa BIOMARKERS PREDICTIVE OF THERAPEUTIC RESPONSIVENESS TO IFNβ AND USES THEREOF
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
ES2818823T3 (es) 2014-02-27 2021-04-14 Biogen Ma Inc Método de evaluación del riesgo de LMP
EA201691896A1 (ru) 2014-03-21 2017-01-30 Аджиос Фармасьютикалз, Инк. Соединения и способы их применения
WO2015172083A1 (en) 2014-05-08 2015-11-12 Biogen Ma Inc. Dimethylfumarate and prodrugs for treatment of multiple sclerosis
US20170269075A1 (en) 2014-05-12 2017-09-21 Biogen Ma Inc. Biomarkers predictive of lupus progression and uses thereof
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
WO2016026978A1 (en) 2014-08-22 2016-02-25 Universite Nice Sophia Antipolis Methods and pharmaceutical compositions for treating drug addiction
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
WO2018013579A1 (en) 2016-07-11 2018-01-18 cARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Sweat as a biofluid for analysis and disease identification
WO2018045162A1 (en) 2016-09-01 2018-03-08 Biogen Ma Inc. Biomarkers predictive of primary progressive multiple sclerosis and uses thereof
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法
CN110192108B (zh) * 2017-01-12 2022-07-19 新加坡科技研究局 检测不同的靶标分析物的存在的方法及其相关的试剂盒
WO2019237119A1 (en) 2018-06-08 2019-12-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and detection methods for onchocerca volvulus infection
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3826649A4 (en) 2018-07-23 2022-07-20 Enclear Therapies, Inc. Methods of treating neurological disorders
WO2020061591A1 (en) 2018-09-21 2020-03-26 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mrna coding for secreted proteins
JP7225713B2 (ja) * 2018-11-09 2023-02-21 東洋紡株式会社 抗ストレプトリジンｏ測定用ラテックス粒子の製造方法
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
WO2020243021A2 (en) 2019-05-24 2020-12-03 Foundation Medicine, Inc. Ntrk fusion molecules and uses thereof
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ， インク． くも膜下液管理方法およびシステム
CN115637284A (zh) * 2021-12-21 2023-01-24 北华大学 呼吸道感染常见革兰阳性菌复合乳胶快速鉴定试剂盒及鉴定方法
CN120174114B (zh) * 2025-05-21 2025-12-02 北京林业大学 长林小蠹特异性lamp引物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3163625A (en) * 1960-04-13 1964-12-29 Du Pont Color-forming monomers and polymers of acrylic acid amides of 3-aminopyrazolone
DE1570672C3 (de) * 1964-06-23 1975-02-06 Gevaert Photo-Producten N.V., Mortsel, Antwerpen (Belgien) Verfahren zur Herstellung von farbphotographischen Silberhalogenidemulsionen
GB1130581A (en) * 1965-01-01 1968-10-16 Gevaert Photo Prod Nv Photographic gelatin compositions containing colour couplers
GB1247688A (en) * 1968-02-26 1971-09-29 Agfa Gevaert Monomeric and polymeric 2-pyrazoline-5-one colour couplers
GB1269355A (en) * 1968-07-18 1972-04-06 Agfa Gevaert A Naamlooze Venno 0-aryl-2-pyrazoline-5-one colour couplers
GB1363230A (en) * 1970-12-16 1974-08-14 Agfa Gevaert Colour couplers and their use in colour photography
GB1453057A (en) * 1973-02-26 1976-10-20 Agfa Gevaert Polymeric colour forming and competing couplers
US4369226A (en) * 1979-03-19 1983-01-18 California Institute Of Technology Polyglutaraldehyde synthesis and protein bonding substrates
DE3064831D1 (en) * 1979-10-15 1983-10-20 Agfa Gevaert Nv Copolymer latex and photographic silver halide materials containing such latex
NL8000173A (nl) * 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4419453A (en) * 1981-09-28 1983-12-06 The Dow Chemical Company Immunological agglutination assays with dyed or colored latex and kits
JPS5975152A (ja) * 1982-10-23 1984-04-27 Tatsuo Suzuta 螢光免疫ラテツクス粒子
EP0136347A1 (en) * 1983-02-25 1985-04-10 Covalent Technology Corporation Insoluble surfaces treated to inhibit non-specific protein binding
US4703017C1 (en) * 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
EP0170746A1 (en) * 1984-08-07 1986-02-12 Covalent Technology Corporation Biologically active material test
US4745075A (en) * 1984-09-06 1988-05-17 Burroughs Wellcome Co. Diagnostic test methods

Also Published As

Publication number Publication date
ATE87743T1 (de) 1993-04-15
EP0227173B1 (en) 1993-03-31
US4837168A (en) 1989-06-06
JP2509201B2 (ja) 1996-06-19
EP0227173A2 (en) 1987-07-01
EP0227173A3 (en) 1989-08-02
DE3688184D1 (de) 1993-05-06
DE3688184T2 (de) 1993-07-08
US5498551A (en) 1996-03-12
JPS62195556A (ja) 1987-08-28
CA1291031C (en) 1991-10-22

Similar Documents

Publication Publication Date Title
EP0227173A3 (en) New method for the detection of specific binding agents and their corresponding bindable substances
AU4147989A (en) Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles
DE69429770D1 (de) Verfahren und analytisches system zur genauen schnellen und einfachen ausführung von fibrinogen-assays
DE69416828D1 (de) Vorrichtung zur chromatographischen bestimmung, die einander entgegenstellbare teile enthalten
BG104275A (en) Method and device for express analysis of tested parameters in biological samples
FI915150A7 (fi) Menetelmät, reagenssit ja testikäyttöpakkaukset biologisten yksiköiden alapopulaatioiden määrittämiseksi
ATE290693T1 (de) Teststreifen zur bestimmung eines analyts in eine flüssige probe
FI903515A0 (fi) Testimenetelmä ja reagenssikitti sitä varten
EP0913690A3 (de) Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren
DE60312513D1 (de) Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100
ATE48157T1 (de) Ein zwitterion als bindungsmittel enthaltende zusammensetzung und testvorrichtung zum nachweis von leukozyten.
DE69117588D1 (de) Zusammensetzung und Verfahren zur Bestimmung von Ketonkörpern
KR890702039A (ko) 1,25-디하이드록시 비타민 d의 분석 방법
DK217783D0 (da) Praeparat, testmateriale samt fremgangsmade til bestemmelse af tilstedevaerelsen af esteraseaktivitet i en flydende forsoegsproeve
DE69736336D1 (de) Verfahren zur messung von blutersatzstoffen
ATE26187T1 (de) Vorrichtung zum homogenen spezifischen bindungsassay, verfahren zu deren herstellung und analytisches verfahren zur anwendung der vorrichtung.
ATE220112T1 (de) Verfahren zum nachweis von störungen des protein c/protein s-systems
DE69808895D1 (de) Leistungssteigerung von bindungsassays mit verwendung mehr als einer markierungsmittel
DE69837155D1 (de) Verfahren zum nachweiss von antikörpern in einer probe
ATE131933T1 (de) Verfahren zur abtrennung und messung von spurbestandteilen
CA2074556A1 (en) Immunological detection method
CA2021658A1 (en) Multiplex immunoassay system
DE69938973D1 (de) Verfahren zur feststellung von einer thiol enthaltenden zusammensetzung
DE69032663D1 (de) Enzymtest und testsatz zur messung zellulärer aktivierung
ATE184109T1 (de) Indikatorreagenzien zum nachweis oder zur messung von analyten, testsatz, der diese enthält, und verfahren zum nachweis oder zur messung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 227173

Country of ref document: ES